ArticleNeurochemical research2026
NOTCH3 Mutations in CADASIL Alter Lipid Metabolism: Insights from Patient Plasma and In Vitro Models.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), the most common monogenic form of cerebral small vessel disease (CSVD), is caused by mutations in NOTCH3. However, the effects of NOTCH3 mutations on lipid metabolism remain poorly understood. In this study, plasma samples from CADASIL patients and matched healthy controls were subjected to lipidomic analysis. Stable 293T cell lines expressing an empty vector (NC), wild-type (WT) NOTCH3, or CADASIL-associated NOTCH3 mutants (R110C, R133C, R1175W, and R544C), as well as hCMEC/D3 cell lines expressing NC, WT, or R544C, were established to investigate lipid metabolic alterations. Lipid droplet (LD) accumulation, cholesterol levels, and the expression of cholesterol transport-related molecules were assessed. Lipidomic profiling revealed significant alterations in plasma lipid profiles in CADASIL patients compared with healthy controls. In 293T cells, LD accumulation was significantly increased in the R110C, R1175W, and R544C groups, but not in the R133C group, whereas cholesterol levels were elevated in all mutant groups. In hCMEC/D3 cells, expression of the R544C mutant markedly promoted cholesterol accumulation and reduced the expression of the cholesterol transporters ABCA1 and ABCG1. These findings indicate that NOTCH3 mutations are associated with disrupted cellular lipid homeostasis and suggest that lipid metabolic dysregulation may represent a potential mechanism contributing to CADASIL pathogenesis.
Indexed as
Identifiers
42627555What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.